Mirum to share Phase 3 AZURE-1 brelovitug topline data in chronic hepatitis delta on Sept. 28 investor call
Bitget2026/09/27 21:00- Mirum Pharmaceuticals scheduled an investor call for Sept. 28, 2026 to release topline Phase 3 AZURE-1 results for brelovitug in chronic hepatitis delta.
- Results have not been presented yet; the event will also include 48-week data from the study’s Phase 2b portion.
- The update is expected to clarify whether brelovitug can support a late-stage path toward potential commercialization in hepatitis delta.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bank of Japan minutes turn hawkish: Most members believe a rate hike is needed soon, with a 70% probability of a hike in December
Minutes from the Bank of Japan show that several members believe a rate hike is needed in the near term, with a roughly 70% probability of an increase in December. Core inflation has met the target for the first time in 30 years, and the current policy rate stands at 1.25%.
Former Chainlink Product Marketing Director Michael Robinson joins Monad Foundation
The Federal Reserve Eyes $1.8 Trillion in “Shadow Credit”: Dallas and New York Fed Launch First Private Credit Survey
The Dallas and New York Federal Reserves have launched an investigation into private credit lending standards, covering an industry worth 1.8 trillions USD, with a minimum threshold of 50 millions USD. The results will be released in the first quarter of 2027.
Tom Lee Says a VIX Signal Points to a Stock Market Bottom
Crypto prices
More
